Progenics Pharmaceuticals Inc

Progenics Pharmaceuticals — Technical Presentation (June 2017)

40 slides from Progenics Pharmaceuticals's technical presentation, Jun 20, 2017

  1. Slide 1: Ultratrace lobenguane I-131 (AZEDRA) in Patients with Malignant or Recurrent Pheochromocytoma/Paraganglioma

    Ultratrace® lobenguane I-131 (AZEDRA™) in Patients with Malignant or Recurrent Pheochromocytoma / Paraganglioma Camilo Jimenez, MD Associate Professor Department of Endocrine Neoplasia and Hormonal Disorders The University of Texas MD Anderson Cancer Center

  2. Slide 2: Outline

    Outline * Anatomical definitions * Clinical manifestations * Therapeutics: * Malignant pheochromocytomas/paragangliomas * Therapeutic Challenges * Phase 2b Clinical Trial with Azedra for Patients with Recurrent or Malignant Pheochromocytoma/Paraganglioma

  3. Slide 3: Anatomical definitions

    Anatomical definitions

  4. Slide 4: Paraganglia

    Paraganglia * Group of neuro- endocrine cells that migrate during embryonic development with components of the parasympathetic and sympathetic ganglia.

  5. Slide 5: Pheochromocytomas

    Pheochromocytomas * Chromaffin (+) tumors originated in the adrenal medulla. They may produce catecholamines such as epinephrine and/or norepinephrine predisposing to cardiovascular disease and other complications. WHO 2004

  6. Slide 6: Slide 6

  7. Slide 7: Paragangliomas

    Paragangliomas * Paragangliomas are tumors that arise from extra- adrenal chromaffin cells and can originate either in the parasympathetic or sympathetic ganglia. * Parasympathetic: chemodectomas, carotid body tumors, glomus jugular tumors, etc. * Sympathetic: thoracic, abdominal, and pelvic tumors.

  8. Slide 8: Slide 8

  9. Slide 9: Clinical Manifestations

    Clinical Manifestations * More than 100 symptoms and signs have been described in association with these tumors. Hypertension, headaches, palpitations, and diaphoresis are the most common ones.

  10. Slide 10: Clinical manifestation

    Clinical manifestation Symptom Headaches Palpitations Diaphoresis Pallor Nausea Weight loss Flushing Fatigue Anxiety — Panic attacks Sustained hypertension Paroxysmal hypertension Orthostatic hypotension Frequency % 60-90 50-70 55-75 40-45 20-40 10-20 20-40 20-40 25-40 Lenders, Lancet 2005

  11. Slide 11: Gastrointestinal disease

    Gastrointestinal disease

  12. Slide 12: Case presentation

    Case presentation * 46 year-old man with history of malignant paraganglioma presents with hypertension, palpitations, headaches, sweats, and constipation for longer than 1 year (last bowel movement was hard and happened 8 days ago). The patient noticed fever, nausea, and lack of appetite. On physica

  13. Slide 13: Case presentation

    Case presentation

  14. Slide 14: Constipation

    Constipation * It happens in 6% of patients * It is usually mild but occasional cases are severe * It may predispose to hemorrhoids, stercoral ulcers, toxic megacolon, bleeding, perforation, and obstruction. * Alpha- and beta-blockers do not treat constipation. Laxatives are required and their chose

  15. Slide 15: Clinical manifestations

    Clinical manifestations * The clinical presentation of these tumors is highly variable and can overlap with the signs and symptoms associated with numerous other non- related clinical conditions. * The critical first step in making the diagnosis is to suspect the presence of a tumor.

  16. Slide 16: Genetics

    Genetics

  17. Slide 17: Strong hereditary background MEN2, VHL, NF1, SDHx

    Strong hereditary background 50 MEN2, VHL, NF1, SDHx, TMEM127, MAX, FH EPAS-1 @ % hereditary cases 1990 2005 2020 Neumann, NEJM, 2001; Amar L. JCO, 2005; Jimenez, JCEM, 2006; Dahia, 2011

  18. Slide 18: Malignant Pheochromocytoma and Paraganglioma

    Malignant Pheochromocytoma and Paraganglioma

  19. Slide 19: Malignant PH or SGP

    Malignant PH or SGP * No molecular or histologic markers exist for determining whether a PH or SPG is malignant * Malignancy is defined only by the presence of metastases * The most common locations of metastatic spread are the lymph ganglia, bones, liver, and lungs * Liver, pancreas, and kidneys ma

  20. Slide 20: Malignant pheochromocytoma

    Malignant pheochromocytoma

  21. Slide 21: Road to Diagnosis

    Road to Diagnosis * Signs/symptoms may be present but the association with a pheochromocytoma/paraganglioma is not made * Patients may present with big tumors and/or distant spread

  22. Slide 22: Treatment Challenges for Malignant Pheo/Para Patients

    Treatment Challenges for Malignant Pheo/Para Patients * High morbidity and mortality rates from: * Excessive catecholamine secretion ¢ Hypertension Cardiovascular complications Gastrointestinal disease Bulky disease for which no curative treatment is available * Low overall survival (OS) rates; only

  23. Slide 23: Current Management of Malignant Pheo/Para

    Current Management of Malignant Pheo/Para * No approved treatments * Most patients treated with chemotherapy or MIBG therapy * Responses limited * Duration of response limited Surgery Many tumors unresectable Localized radiotherapy Disease is frequently extensive Chemotherapy Toxicity; limited effic

  24. Slide 24: Overall survival comparing surgical resection versus no surgery

    Overall survival comparing surgical resection of the primary tumor versus no surgery Alejandro Roman, Annals of Surgery, 2017

  25. Slide 25: Malignant pheochromocytoma

    Malignant pheochromocytoma

  26. Slide 26: Meta-Iodobenzylguanidine (MIBG)

    Meta-lodobenzylguanidine (MIBG) * Described by Wieland et al in 1979 at the University of Michigan * lodination in the meta position * Stable and highly resistant to in vivo metabolism + ~90% excreted intact in the urine * 40-50% within 24 hours * MIBG is not a norepinephrine analog * Substrate for

  27. Slide 27: Norepinephrine Transporter

    Norepinephrine Transporter

  28. Slide 28: Rationale for the use of MIBG in patients with pheo/para

    Rationale for the use of MIBG in patients with pheo/para * NET is highly expressed in tumors of neural crest origin such as pheo/para and neuroblastoma * Radio iodinated MIBG has been used for both diagnostic and therapeutic applications for neuroendocrine tumors * Conventional (carrier added) |-131

  29. Slide 29: Ultratrace vs. Conventional I-131 MIBG

    Ultratrace® vs. Conventional I|-131 MIBG Similarity: = Both MIBG labeled at the meta position with I-131 Differences: Manufacturing From solid aoe precursor | By simple isotope exchange process (resin) Specific activity of High drug product Unlabeled MIBG Large amount each dose Safety No cold MIBG,

  30. Slide 30: Only 1 in 1,000 molecules of MIBG contains I-131

    Only 3 in 1,000 molecules of MIBG contains [1341]

  31. Slide 31: Every Azedra molecule contains I-131

    Every Azedra molecule contains [4341]

  32. Slide 32: Phase 2b trial of Azedra in Malignant or Recurrent Pheochromocytoma and Paraganglioma

    Phase 2b trial of Azedra in Malignant or Recurrent Pheochromocytoma and Paraganglioma

  33. Slide 33: Phase 2b Trial: Key eligibility and study endpoints

    Phase 2b Trial: Key eligibility and * Primary Endpoints: * Reduction of antihypertensive medications by 2 50% for at least 6 months * Secondary Endpoints: + Safety * Tumor Response by RECIST and tumor markers * Overall Survival study endpoints ° Key Eligibility: * Documented pheo/para Ineligible for

  34. Slide 34: Trial Design

    Trial Design * Multi-center, open label * Patients receive dosimetry dose to determine tumor avidity to Azedra * Patients receive 2 therapy doses, 3 months apart * Enrolled 68 patients

  35. Slide 35: Trial achieved primary endpoint

    Trial achieved primary endpoint * Met the primary endpoint evaluating the proportion of patients who achieved a 250% reduction of all antihypertensive medication for at least six months. * Under the study protocol, the primary endpoint is achieved if the lower limit of the two-sided 95% confidence i

  36. Slide 36: Favorable Tumor Responses

    Favorable Tumor Responses * Key secondary endpoint: the proportion of patients with overall tumor response as measured by RECIST * 92.2% of evaluable patients (59/64) who received at least one AZEDRA therapeutic dose achieved partial response or stable disease Overall Tumor Response Assessment per R

  37. Slide 37: Safety Overview

    Safety Overview * Generally well tolerated * Most common TEAEs were consistent with prior studies: * Nausea Thrombocytopenia Anemia Fatigue Leukopenia Neutropenia, consistent with prior studies

  38. Slide 38: Conclusions

    Conclusions * The trial met the primary endpoint evaluating the proportion of patients who achieved a 250% reduction of all antihypertensive medication for at least six months * 92.2% of evaluable patients (59/64) who received at least one AZEDRA therapeutic dose achieved partial response or stable

  39. Slide 39: Conclusions

    Conclusions ¢ Azedra was generally well tolerated * AEs consistent with prior studies * Azedra may be a useful treatment for patients with iobenguane-avid metastatic and/or recurrent pheochromocytoma/paraganglioma, an orphan disease with no FDA approved therapies

  40. Slide 40: cjimenez@mdanderson.org

    cjimenez@mdanderson.org

Progenics Pharmaceuticals — Technical Presentation (June 2017) on 6ix